TREATMENT AND PREVENTION OF ANGINA PECTORIS, MYOCARDIAL INFARCTION, ARRHYTHMIAS, AND OTHER CONDITIONS WITH BETA-BLOCKERS

Main Article Content

Muhammad Shahzad Zafar, Muhammad Naeem Khan, Prof. Dr. Anurag Rawat, Dr. Jaweria Shaheen, Nuuseey, Atta Ur Rehman
Tariq Rafique
Nosheen Akhtar
Rabia Taj
Almas Faryal Nizam

Keywords

Angina pectoris, beta-blockers, ischemic, cardiovascular and heart disease

Abstract

Beta-blockers are used to treat several illnesses, including arrhythmias, myocardial infarction, angina pectoris, and others, as well as to avoid these conditions. Patients who are diagnosed with ischemic heart disease usually report experiencing angina pectoris, which is a form of the condition that is fundamentally significant. The modified Delphi method was utilized in order to assess the level of consensus among specialists about the therapeutic appropriateness of utilizing beta-blockers for the treatment of angina pectoris, myocardial infarction, and cardiac arrhythmias in a variety of clinical practice settings. A first panel of fifteen claims was offered by the CE, which was based on the data that was found in the literature as well as his personal clinical experience. The CS then put these assertions to a vote. Because of their efficacy in preventing and treating recurrent angina and ischemic episodes, as well as the arrhythmias that accompany them, beta-blockers are a staple of pharmacological therapy for persons who suffer from ischemic heart disease.

Abstract 460 | PDF Downloads 69

References

Baldaçara, L., de Gouvêa Pettersen, A., da Silveira Leite, V., Ismael, F., Motta, C. P., Freitas, R. A., . . . Barbosa, L. (2022). Brazilian Psychiatric Association Consensus for the Management of Acute Intoxication. General management and specific interventions for drugs of abuse. Trends in psychiatry and psychotherapy(AheadOfPrint), 0-0.
Barton, A. K., McGowan, M., Smyth, A., Wright, G. A., & Gardner, R. S. (2020). Classification and choice of antiarrhythmic therapies. Prescriber, 31(3), 11-17.
Chakraborty, R. (2023). Nicorandil, Novel Potassium Adenosine Triphosphate Channel (K+ ATP) Opener in Ischemia With Non-Obstructive Coronary Arteries (INOCA) and Atherosclerotic Cardiovascular Disease (ASCVD): Delphi Consensus Statement. Cureus, 15(1).
Diaconu, C. C., Marcu, D. R., Bratu, O. G., Stanescu, A. M. A., Gheorghe, G., Hlescu, A. A., . . . Manea, M. (2019). Beta-blockers in cardiovascular therapy: A review. Journal of Mind and Medical Sciences, 6(2), 216-223.
Farmakis, I. T., Pyrgidis, N., Doundoulakis, I., Mykoniatis, I., Akrivos, E., & Giannakoulas, G. (2022). Effects of major antihypertensive drug classes on erectile function: a network meta-analysis. Cardiovascular Drugs and Therapy, 36(5), 903-914.
Gillessen, A., Randerath, O., Mockel, L., Noetel, A., & Seiler, D. (2019). A single pill combining bisoprolol and amlodipine: An open-label, multi-dose, single-sequence study to investigate potential pharmacokinetic drug-drug interaction between the two compounds in healthy adult volunteers. J Primary Health Care Gen Practice, 29, 1-6.
Gupta, A., Gupta, J., & Gupta, A. (2023). Chemistry of Beta-blockers and their role in the Cardiovascular Disorders. Int. J. Curr. Res. Chem. Pharm. Sci, 10(2), 1-6.
Habib, S., Alam, M., Mustafa, M., & Verma, A. K. Role of Beta-Blockers as an Effective Cardio protective Agents, an insight in to Tackling with Cardiovascular Diseases (CVDs) and Hypertension.
Heriansyah, T., Nur Chomsy, I., Febrianda, L., Farahiya Hadi, T., & Andri Wihastuti, T. (2020). The potential benefit of beta-blockers for the management of COVID-19 protocol therapy-induced QT prolongation: a literature review. Scientia Pharmaceutica, 88(4), 55.
Hiraoka, E., Tanabe, K., Izuta, S., Kubota, T., Kohsaka, S., Kozuki, A., . . . Nagai, T. (2023). JCS 2022 Guideline on Perioperative Cardiovascular Assessment and Management for Non-Cardiac Surgery. Circulation Journal, CJ-22-0609.
Joshi, S., Tepper, S. J., Lucas, S., Rasmussen, S., & Nelson, R. (2021). A narrative review of the importance of pharmacokinetics and drug–drug interactions of preventive therapies in migraine management. Headache: The Journal of Head and Face Pain, 61(6), 838-853.
Kong, B., Liu, Y., Hu, H., Wang, L., Fan, Y., Mei, Y., & Liu, W. (2014). Left atrial appendage morphology in patients with atrial fibrillation in China: implications for stroke risk assessment from a single center study. Chinese Medical Journal, 127(24), 4210-4214.
Kotalczyk, A., Mazurek, M., Kalarus, Z., Potpara, T. S., & Lip, G. Y. (2021). Stroke prevention strategies in high-risk patients with atrial fibrillation. Nature Reviews Cardiology, 18(4), 276-290.
LAJOIE, M., & DC, C. THE DIVERSE PROPERTIES AND USES OF BETA-BLOCKERS.
Mancia, G., Kjeldsen, S. E., Kreutz, R., Pathak, A., Grassi, G., & Esler, M. (2022). Individualized beta-blocker treatment for high blood pressure dictated by medical comorbidities: indications beyond the 2018 European Society of Cardiology/European Society of Hypertension Guidelines. Hypertension, 79(6), 1153-1166.
Martinez-Milla, J., Raposeiras-Roubin, S., Pascual-Figal, D. A., & Ibanez, B. (2019). Role of beta-blockers in cardiovascular disease in 2019. Revista Española de Cardiología (English Edition), 72(10), 844-852.
Ponikowski, P., Alemayehu, W., Oto, A., Bahit, M. C., Noori, E., Patel, M. J., . . . Lam, C. S. (2021). Vericiguat in patients with atrial fibrillation and heart failure with reduced ejection fraction: insights from the VICTORIA trial. European journal of heart failure, 23(8), 1300-1312.
Sabah, Z., Wani, J., Deajim, M., Zomia, A. S. A., Asiri, A., Alqahtani, A. A., . . . Raj, B. (2023). Serum Magnesium in Patients With Acute Myocardial Infarction and Its Effect on Cardiac Complications and Mortality in Myocardial Infarction Patients. Cureus, 15(4).
Sahai, S. K., Balonov, K., Bentov, N., Bierle, D. M. M., Browning, L. M., Cummings III, K. C., . . . Oprea, A. D. (2022). Preoperative Management of Cardiovascular Medications: A Society for Perioperative Assessment and Quality Improvement (SPAQI) Consensus Statement. Paper presented at the Mayo Clinic Proceedings.
Santos, J., António, N., Rocha, M., & Fortuna, A. (2020). Impact of direct oral anticoagulant off‐label doses on clinical outcomes of atrial fibrillation patients: a systematic review. British Journal of Clinical Pharmacology, 86(3), 533-547.
Satyanarayana, T., Palepu, S., Parvathi, T., Krishna, K. C., Parveen, S., & Prathyusha, B. (2019). Medical survey on Cardiovascular Disorders. Journal of Drug Delivery and Therapeutics, 9(2-s), 72-75.
Seiffge, D. J., De Marchis, G. M., Koga, M., Paciaroni, M., Wilson, D., Cappellari, M., . . . Arihiro, S. (2020). Ischemic stroke despite oral anticoagulant therapy in patients with atrial fibrillation. Annals of neurology, 87(5), 677-687.
Steffel, J., Collins, R., Antz, M., Cornu, P., Desteghe, L., Haeusler, K. G., . . . Rowell, N. (2021). 2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. EP Europace, 23(10), 1612-1676.
Swapna, G., Maheswaramma, K. S., & Reddy, K. B. Atenolol And Nifedipine Combination Is Better Than Monotherapy: A New Era In Novel Drug Delivery For Hypertension.
Viigimaa, M., Vlachopoulos, C., Doumas, M., Wolf, J., Imprialos, K., Terentes-Printzios, D., . . . Stavropoulos, K. (2020). Update of the position paper on arterial hypertension and erectile dysfunction. Journal of Hypertension, 38(7), 1220-1234.
Watson, M. P., Bennett, M., Hamilton, C., Hill, L., & McNally, O. (2022). Rate vs rhythm: beta blockers and antiarrhythmics as pharmacological options for the treatment of postoperative atrial fibrillation. British Journal of Cardiac Nursing, 17(11), 1-7.
Yarmukhamedova, S. K., Alisherovna, K. M., Tashtemirovna, E. M. m., & Nizamitdinovich, K. S. (2023). The Effectiveness of Trimetazidine in Arrhythmias. Miasto Przyszłości, 33, 215-221.

Most read articles by the same author(s)

1 2 > >>